ClinicalTrials.gg
Active, not recruitingNCT07783373Updated Aug 24, 2026

Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia

An observational study in Schizophrenia, sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Bristol-Myers Squibb · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Schizophrenia by Bristol-Myers Squibb — 8 open to participants now, 9 under way, 4 of them phase 3. Schizophrenia · Bristol-Myers Squibb.

Started
2026
with 6 others
Observational
4 of 21
2 open now
Registered
21st of 21
by date

Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, this one is one of 7 that started in 2026, is one of 4 observational ones, and was the 21st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

8 of the 21 studies in Schizophrenia by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Schizophrenia by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study will evaluate the long-term real-world safety of xanomeline-trospium chloride in adults with schizophrenia receiving routine clinical care in the United States.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Xanomeline-trospium chloride
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include adults in the United States with schizophrenia who initiate xanomeline-trospium chloride or comparator oral antipsychotics between 27 September 2024 and 26 September 2027.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the index date.
  • Either:

    1. ≥1 inpatient/emergency room claim with a primary diagnosis of schizophrenia; or
    2. ≥2 office visit claims with a diagnosis of schizophrenia; or
    3. ≥2 qualifying claims with a diagnosis of schizophrenia plus qualifying psychiatric Current Procedural Terminology (CPT) services.
  • ≥1 prescription dispensation claim for xanomeline-trospium chloride or a comparator oral antipsychotic during the study period.
  • Continuous medical and pharmacy coverage during the 183 days before and including the index date.
  • No prescription claims for xanomeline-trospium chloride or the index comparator oral antipsychotic during the 183-day baseline period.
  • Primary objective: earliest eligible treatment episode included once per participant.
  • Secondary objectives: eligible participants may be selected more than once for inclusion in the study. The treatment episode closest to the start of the study period that is eligible for inclusion will be selected as the first treatment episode for each individual. If an individual switches treatment group during the follow-up period, then this will result in another treatment episode for that individual.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to xanomeline-trospium chloride or the index comparator oral antipsychotic during the 183-day baseline period.
  • Age \<18 years.
  • Primary outcome: urinary retention during the baseline period or on the index date.
  • Secondary outcome: occurrence of sinus tachycardia, syncope resulting from orthostatic hypotension, hypertension, or liver injury during the baseline period or on the index date.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Xanomeline-trospium chloride

    Participants who initiate xanomeline-trospium chloride treatment

    Drug: xanomeline-trospium chloride

  • Comparator Oral Antipsychotics

    Participants who initiate first-generation or second-generation oral antipsychotics

    Drug: Oral antipsychotics

Interventions

  • Drugxanomeline-trospium chloride

    As per product label

  • As per product label

06

What researchers measure

Primary outcomes

  1. Number of participants with incident urinary retention

    Time frame: Up to 3-years

Secondary outcomes

  1. Number of participants with incident biliary disorders

    Time frame: Up to 3-years

  2. Number of participants with incident sinus tachycardia

    Time frame: Up to 3-years

  3. Number of participants with incident syncope resulting from orthostatic hypotension

    Time frame: Up to 3-years

  4. Number of participants with incident hypertension

    Time frame: Up to 3-years

  5. Number of participants with incident liver injury

    Time frame: Up to 3-years

07

Study locations

1 site
  • Local Institution - 0001
    Suwanee, Georgia 30024, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Aug 24, 2026
StartActual
May 1, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Apr 26, 2028
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07783373
Responsible party
Sponsor
First posted
Aug 24, 2026
Start date
May 1, 2026
Primary completion
Sep 26, 2027 (estimated)
Completion
Apr 26, 2028 (estimated)
Last update
Aug 24, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion